LLY

794.13

+3.06%↑

UNH

604.01

+1.36%↑

JNJ

157.19

-0.46%↓

NVO

106.56

+1.26%↑

ABBV

200.33

-0.66%↓

LLY

794.13

+3.06%↑

UNH

604.01

+1.36%↑

JNJ

157.19

-0.46%↓

NVO

106.56

+1.26%↑

ABBV

200.33

-0.66%↓

LLY

794.13

+3.06%↑

UNH

604.01

+1.36%↑

JNJ

157.19

-0.46%↓

NVO

106.56

+1.26%↑

ABBV

200.33

-0.66%↓

LLY

794.13

+3.06%↑

UNH

604.01

+1.36%↑

JNJ

157.19

-0.46%↓

NVO

106.56

+1.26%↑

ABBV

200.33

-0.66%↓

LLY

794.13

+3.06%↑

UNH

604.01

+1.36%↑

JNJ

157.19

-0.46%↓

NVO

106.56

+1.26%↑

ABBV

200.33

-0.66%↓

Search

Amarin Corp PLC ADR

Отворен

0.57 -3.39

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.57

Максимум

0.59

Ключови измерители

By Trading Economics

Приходи

-27M

-25M

Продажби

-25M

42M

EPS

-0.06

Марж на печалбата

-59.421

EBITDA

13M

237K

Пазарни показатели

By TradingEconomics

Пазарна капитализация

6.1M

244M

Предишно отваряне

3.96

Предишно затваряне

0.57

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Amarin Corp PLC ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.11.2024 г., 23:28 ч. UTC

Печалби

DBS Third-Quarter Net Beats Estimates; Plans Share Buyback

6.11.2024 г., 22:28 ч. UTC

Топ новини

Canada Orders TikTok Canada Unit to Dissolve Operations on National-Security Concerns

6.11.2024 г., 22:25 ч. UTC

Печалби

Gilead Sciences Post Higher 3Q Revenue, Raises Fiscal Year Guidance

6.11.2024 г., 22:09 ч. UTC

Печалби

NAB Raises Dividend Despite a 6.1% Fall in Annual Profit -- Update

6.11.2024 г., 23:46 ч. UTC

Печалби

Qualcomm Stock Jumps on Solid Earnings. Watch for These Risks. -- Barrons.com

6.11.2024 г., 23:08 ч. UTC

Печалби

Kakao 3Q Net Profit Missed FactSet-Compiled Consensus

6.11.2024 г., 23:07 ч. UTC

Печалби

Kakao Corp. 3Q Net KRW78.51B Vs. Net KRW36.86B >035720.SE

6.11.2024 г., 23:07 ч. UTC

Печалби

Kakao Corp. 3Q Oper Pft KRW130.53B Vs. Pft KRW124.31B >035720.SE

6.11.2024 г., 23:07 ч. UTC

Печалби

Kakao Corp. 3Q Rev KRW1.921T Vs. KRW2.011T >035720.SE

6.11.2024 г., 23:05 ч. UTC

Печалби

Franco-Nevada 3Q EPS 79c >FNV

6.11.2024 г., 23:05 ч. UTC

Печалби

Franco-Nevada 3Q Rev $275.7M >FNV

6.11.2024 г., 23:03 ч. UTC

Печалби

APA 3Q Rev $2.54B >APA

6.11.2024 г., 23:03 ч. UTC

Печалби

APA 3Q Loss/Shr 60c >APA

6.11.2024 г., 22:47 ч. UTC

Печалби

DBS Board Sets Up S$3.0B Share-Buyback Program >D05.SG

6.11.2024 г., 22:45 ч. UTC

Печалби

DBS Declares 3Q Dividend of S$0.54 >D05.SG

6.11.2024 г., 22:44 ч. UTC

Печалби

DBS 3Q Net Interest Income S$3.80B Vs. S$3.68B >D05.SG

6.11.2024 г., 22:44 ч. UTC

Печалби

DBS 3Q Net S$3.03B Vs. Net S$2.63B >D05.SG

6.11.2024 г., 22:44 ч. UTC

Печалби

DBS 3Q Total Income S$5.75B Vs. S$5.19B >D05.SG

6.11.2024 г., 22:34 ч. UTC

Печалби

Nutrien 3Q Sales $5.35B >NTR.T

6.11.2024 г., 22:34 ч. UTC

Печалби

Nutrien 3Q EPS 4c >NTR.T

6.11.2024 г., 22:24 ч. UTC

Топ новини

Stocks Soar, Dollar Jumps as Trump's Win Reverberates Through Markets -- Update

6.11.2024 г., 22:17 ч. UTC

Печалби

Arm Delivers Beat-And-Raise Report But Keeps Full-Year Outlook Unchanged -- IBD

6.11.2024 г., 22:10 ч. UTC

Печалби

Gilead Sciences Post Higher 3Q Revenue, Raises FY Guidance

6.11.2024 г., 22:09 ч. UTC

Пазарно говорене
Печалби

Take-Two Boss Is Eying Microsoft's Strategy With 'Call of Duty' -- Market Talk

6.11.2024 г., 22:09 ч. UTC

Печалби

Manulife 3Q Net C$1.8B >MFC

6.11.2024 г., 22:09 ч. UTC

Печалби

Manulife 3Q EPS C$1.00 >MFC

6.11.2024 г., 22:07 ч. UTC

Печалби

Ashland 4Q EPS 39c >ASH

6.11.2024 г., 22:07 ч. UTC

Печалби

Ashland 4Q Sales $522M >ASH

6.11.2024 г., 22:07 ч. UTC

Печалби

Ashland Sees FY25 Sales $1.90B-$2.05B >ASH

6.11.2024 г., 22:03 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Amarin Corp PLC ADR Прогноза

Консенсусна оценка

By TipRanks

0 ratings

0

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

0.58 / 0.6002Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

No Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Amarin Corp PLC ADR

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.